Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07092514 · ClinicalTrials.gov registry record · Phase 2

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

A Phase 2 study of Thyroid Cancer and Cancer of the Thyroid, sponsored by Washington University School of Medicine.

Recruiting
Registry status
Phase 2
Development phase
34
Enrollment target
1
Study location

NCT07092514 is a Phase 2 study of Thyroid Cancer and Cancer of the Thyroid that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 34 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07092514, a Phase 2 study of Thyroid Cancer and Cancer of the Thyroid, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
Phase 2
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).

Conditions Studied

Thyroid Cancer Cancer of the Thyroid

Interventions

  • DRUG Lenvatinib

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2025-10-14
Est. Completion 2034-10-31
Phase Phase 2

Sponsor

Washington University School of Medicine

1,502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07092514

The ClinicalTrials.gov registry entry for NCT07092514 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lenvatinib is the first listed.

NCT07092514 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT07092514 about?

NCT07092514 is a clinical study titled "Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)". This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).

What is the current status of trial NCT07092514?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2025-10-14. Estimated completion is 2034-10-31.

What conditions does trial NCT07092514 study?

This clinical trial studies the following conditions: Thyroid Cancer, Cancer of the Thyroid.

What interventions are being tested in trial NCT07092514?

The interventions under investigation include: Lenvatinib (DRUG).

Who is sponsoring clinical trial NCT07092514?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07092514 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thyroid Cancer

All registered trials for this condition

Cancer of the Thyroid

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.